companies / tavobio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 2,081,9322.1M | ○ |
|---|---|---|
| founded | null | |
| hq | MEMPHIS, Tennessee | |
| industry | unknown | |
| stage | null |
Tavo Biotherapeutics develops therapies for ophthalmic neurodegeneration, with a focus on glaucoma and retinal diseases. It targets patients losing vision to glaucoma and the ophthalmologists treating them. Programs aim at neuroprotective and disease-modifying mechanisms in eye care.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-01-01 | grant | 2,081,9322.1M | null | ○ |
Google Analytics, Google Tag Manager, Framer Sites, MongoDB, Node.js, React 16.13.1
| fact | status | src |
|---|---|---|
| Grant, $2.1M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |